Aegerion Pharmaceuticals Receives European Approval for LOJUXTA(TM) (lomitapide) to Treat Homozygous Familial Hypercholesterolemia (HoFH)

(GLOBE NEWSWIRE via COMTEX) Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of novel, life-altering therapies for patients with debilitating, often fatal, rare diseases, announced that the European Commission has approved LOJUXTA(TM) (lomitapide) hard capsules as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolemia (HoFH).